[Federal Register Volume 67, Number 85 (Thursday, May 2, 2002)]
[Notices]
[Page 22101]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-10926]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: 1,8 Naphthalimide Imidazo 
[4,5,1-de] Acridones With Anti-Tumor Activity

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(I), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice the invention embodied in U.S. Patent 
Application 60/187,991 filed on March 7, 2000, entitled ``1,8 
Naphthalimide Imidazo [4,5,1-de] Acridones with Anti-Tumor Activity,'' 
to Avalon Pharmaceuticals, having a place of business in Gaithersburg, 
MD. The aforementioned patent rights have been assigned to the United 
States of America.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before July 1, 
2002, will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Wendy R. Sanhai, Ph.D., Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804; e-mail: [email protected]; 
Telephone: (301) 496-7056, ext. 244; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: This invention relates to the general fields 
of pharmaceuticals and cancer chemotherapy, particularly to the areas 
of cytotoxic antitumor agents and DNA intercalating agents. The lead 
imidazoacridone compound which will be the target of development of the 
exclusive licensee is WMC79, a novel synthetic agent with high 
selectivity and potency against colon, pancreatic and hematopoietic 
tumors. WMC79 is a novel synthetic agent with very potent but highly 
selective activity against colon cancer, pancreatic cancer as well as 
hematopoietic tumors. Preliminary data show that WMC79 is very active 
against colon cancer and pancreatic cancer xenografted into nude mice 
and is very well tolerated at doses that produce a strong anti-tumor 
effect.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The field of use may be limited to the development of a drug for 
human administration, having therapeutic and pharmaceutical uses as an 
anti-cancer agent.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 24, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 02-10926 Filed 5-1-02; 8:45 am]
BILLING CODE 4140-01-P